Cited by 70Attention Deficit Hyperactivity DisorderObsessive-Compulsive Spectrum DisordersStuttering Research and Treatment

First-onset tics in patients with attention-deficit–hyperactivity disorder: impact of stimulants

Roessner, Veit, Robatzek, Monika, Knapp, Guido, Banaschewski, Tobias, Rothenberger, Aribert·2006·Developmental Medicine & Child Neurology

Abstract

First-onset tics during stimulant treatment of attention-deficit-hyperactivity disorder (ADHD) are clinically relevant and remain a matter of scientific debate. Because there are limited clinical trials analyzing the risk of first-onset tics in stimulant-treated ADHD, a comprehensive evaluation is required for evidence-based clinical recommendations. An analysis of studies with high methodological quality (i.e. double-blind placebo-controlled) on first-onset tics during stimulant treatment of ADHD revealed that there seems to be no elevated risk of first-onset tics in children undergoing this treatment. Although a close temporal relationship might be seen in a few patients, the role of treatment duration, dose of stimulant, genetic vulnerability, and developmental aspects need to be further explored to clarify possible pathophysiological mechanisms of tic emergence under stimulant treatment. The results of high quality studies, in addition to specialized studies with methodological limitations, suggest that stimulants are the criterion standard for the safe and successful treatment of ADHD.

Integrity signals

Registry

Crossref · 10.1017/s0012162206001290

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several recent reviews indicate that stimulants are adequately safe in patients with both ADHD and tic disorders and should not be disregarded when planning treatment for ADHD in these individuals.

    “Several recent reviews [24, 119, 124] indicate that stimulants are adequately safe in patients with both ADHD and TD and should not be disregarded when planning treatment for ADHD in these individuals.”
  • The precipitation of first-onset tics during treatment with methylphenidate was found not to be different from placebo (range 0-20%), according to a review that examined predominantly short-term studies but included up to 4 years' duration of monitoring.

    “The precipitation of first-onset tics during treatment with methylphenidate was found not to be different from placebo (range 0–20%), according to a review that examined predominantly short-term studies, but included up to 4 years’ duration of monitoring [119].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Roessner, V., Robatzek, M., Knapp, G., Banaschewski, T., & Rothenberger, A.
Affiliations
  • University of Göttingen (DE)
  • TU Dortmund University (DE)
Venue
Developmental Medicine & Child Neurology
Publisher
Wiley
Published
2006-06-19
Volume
48
Issue
07
Pages
616
ISSN
  • 0012-1622 (ISSN-L)
  • 1469-8749
OpenAlex
W1997290932
Cited by
70
References
63
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 2 · 2017: 2 · 2016: 3 · 2015: 2 · 2014: 8 · 2013: 5 · 2012: 4
FWCI
4.46
Type
journal article
Language
en
Open access
closed
Locations
  • Developmental Medicine & Child Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Clinical Psychology › Stuttering Research and Treatment
Keywords
attention deficit hyperactivity disorder, stimulant medication, children, treatment safety, genetic susceptibility, treatment duration
MeSH terms
Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dose-Response Relationship, Drug, Humans, Risk Factors, Tic Disorders, Tics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review